Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer  by Liu, Wei-Hsin et al.
 Case Report  
Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based 
Regimens for HER2-positive Locally Advanced Breast Cancer 
Wei-Hsin Liu1*, Mei-Ching Liu1, Ben-Long Yu2, Skye Hung-Chun Cheng3, Ming-Yuan Li4, 
Chi-Feng Chung1, Tzung-De Wang5, Chi-Feng Hung5 
1Division of Hematology and Oncology, Department of Internal Medicine, Koo Foundation Sun Yat-Sen Cancer Center, 
Taipei, Taiwan 
2Division of General Surgery, Department of Surgery, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan 
3Department of Radiation Oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan 
4Department of Pathology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan 
5Department of Gynecology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan  
Abstract. 
Trastuzumab, a humanized monoclonal antibody directed against the external domain of 
the HER-2 protein, has shown remarkable activity against HER-2 positive breast cancer. Con-
sequently, the use of adjuvant trastuzumab plus chemotherapy in patients with HER2-positive 
stage breast cancer (stage I to III) has become the standard treatment option. However, the role 
of trastuzumab in neoadjuvant treatment therapy is still uncertain. An increasing number of 
clinical trials and inadequate analysis show the benefit of adding trastuzumab to chemotherapy 
in the neoadjuvant setting. We report a case of HER2-positive locally advanced breast cancer in 
a patient who received cytotoxic agents concomitant with trastuzumab as neoadjuvant therapy, 
and also review the published literature. The patient achieved pathological complete response, 
and remained disease-free for more than 5 years. 
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中文摘要 
  賀癌平(Trastuzumab)是一種作用於人類表皮生長因子受體 II (HER-2)的單株抗體。目
前賀癌平已證實對於 HER-2 過度表現的乳癌有臨床上的效益。針對初期乳癌(第一期至第
journal homepage:www.cos.org.tw/web/index.asp
台灣癌症醫誌 (J. Cancer Res. Pract.) 1(2), 163-171, 2014 DOI: 10.6323/JCRP.2014.1.2.11
Open access under CC BY-NC-ND license.
 三期)術後的輔助性治療，賀癌平搭配化學治療為目前治療的準則。然而，針對局部晚期
乳癌術前所給予的前導性治療，賀癌平所扮演的角色目前仍不確定。但有越來越多的文
獻指出，賀癌平合併化學治療作為局部晚期乳癌的前導性治療有臨床上的助益。我們於
此做一個個案報告，病患是一位 47 歲女性，診斷為 HER-2 陽性的局部晚期乳癌。病患接
受化學治療合併賀癌平作為前導性治療，術後達病理性完全反應，且目前超過 5 年無疾
病復發證據。最後，我們對於賀癌平在前導性治療所扮演的角色做了文獻回顧。 
 
關鍵字: 賀癌平、局部晚期乳癌、前導性治療、病理性完全反應 
INTRODUCTION 
Locally advanced breast cancer (LABC) accounts 
for 6-10% of new cases of breast cancer, and has a 
worse prognosis than early operable disease [1]. Mul-
tidisciplinary therapy, including primary systemic 
therapy, has become the favored treatment choice for 
these patients. Primary systemic therapy (also known 
as neoadjuvant therapy or preoperative therapy) yields 
outcomes (disease-free survival and overall survival) 
equivalent to adjuvant therapy, but further provides 
the benefit of tumor downstaging, improving patient 
operability and shows enhanced breast conservation 
rates [2,3]. Currently, neoadjuvant systemic therapy 
has been applied to these patients as the standard 
treatment strategy [4]. 
Anthracycline-based and taxane-based therapies 
are frequently used as preoperative treatments. The 
landmark study by Wolmark et al. in 2001 (NSABP 
B-18) demonstrated that patients who had a pathologic 
complete response (pCR) to neoadjuvant therapy had 
an improved disease-free survival (DFS) and overall 
survival (OS) compared to those who did not achieve 
a pCR [5]. Patients with human epidermal growth 
factor 2 (HER2)-positive cancers have a relative high 
rate of pathologic complete response to neoadjuvant 
chemotherapy, particularly if treatment includes a 
HER2-directed agent, such as trastuzumab [6]. Be-
cause achieving pathological complete response after 
neoadjuvant chemotherapy predicts favorable progno-
sis, the addition of trastuzumab to cytotoxic therapy 
has led to a considerable increase in DFS and OS of 
HER2-positive breast cancer in a neoadjuvant setting 
[7]. 
We report a case of HER2-positive locally ad-
vanced breast cancer, where the patient received cyto-
toxic agents concomitant with trastuzumab as neoad-
juvant therapy; she achieved pathological complete 
response, and was disease-free for more than 3 years. 
Threreafter, we review the literature focusing on re-
cent advances in anti-HER2 neoadjuvant therapy in 
breast cancer. 
 
CASE REPORT 
The patient is a 47 year-old premenopausal wom-
an, who reported generally good health prior to her 
current medical treatment. One year ago, she palpated 
a right breast lump, but did not initially seek medical 
attention for this problem. However, the breast lesion 
enlarged gradually within one year. She came to 
KFSYSCC in May 2008. Initial physical examination 
upon her first visit revealed an ill-defined mass 6 x 5 
cm in size in the OUQ of the right breast. Grossly, 
there was no sign of skin invasion or nipple discharge. 
The lesion was fixed and its consistency was hard and 
no palpable lymph nodes in the neck or armpits were 
found. Breast sonography disclosed multiple hy-
poechoic ovoid lesions with the largest one measuring 
3.68 cm, 9:30 o’clock direction/ 3 cm away from the  
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Figure 1. (A) Breast sonography before treatment re-
vealed a large lesion, measured at 3.68 cm 
in diameter, hypoechoic and with lobulated 
margins. (B) After four cycles of neoadju-
vant therapy, the lesion became isoechoic 
and smaller with the size of 1.88 cm in di-
ameter 
 
 
nipple with lobulated margins and increased vascular-
ity (Figure 1A). Additionally, an ovoid lymph node 
with fatty hilum measuring 1.2 cm located at the right 
axillar was also reported. Subsequent breast MRI fur-
ther revealed several hyperintense nodules, with the 
largest one measuring 3 cm found in the superior lat-
eral aspect of the right breast. Needle biopsy revealed 
infiltrating ductal carcinoma of nuclear grade 3, ER 
negative, PR negative and HER-2/neu 3 positive. 
There was no evidence of distant metastases, includ-
ing lung, liver and bone. Under the preliminary im-
pression of locally advanced breast cancer/ invasive 
ductal carcinoma, induction chemotherapy was pro-
posed to the patient. 
We explained the treatment rationale, the schedule, 
the benefits and the side effects to the patient and her 
family. Thereafter, a regimen of induction chemother-
apy with four cycles of docetaxel/cisplatin and 
trastuzumab was planned.  
The first course was given on June 9, 2008. The 
initial doses of docetaxel and cisplatin were started 
from 60 mg/m^2 and 60 mg/m^2, respectively, con-
current with the loading dose of trastuzumab (4 mg/kg), 
followed by trastuzumab alone (2 mg/m^2) as mainte-
nance dose in the subsequent two weeks.  
The second course of induction chemotherapy was 
given three weeks later (July 1, 2008). After one 
course of induction chemotherapy, the tumor shrank to 
4 x 3.5 cm, and had a softer consistency. Then we es-
calated the dose of docetaxel to 75 mg/m^2, where a 
total four cycles every three weeks were given. The 
tumor size continued to gradually decrease, and the 
consistency became increasingly softer. After 4 cycles 
of induction chemotherapy, the pre-operative evalua-
tion disclosed that the tumor shrank to 2.5 x 2.5 cm. 
Pre-surgical breast ultrasound revealed a primary tu-
mor with sized 1.88 cm in diameter, which was locat-
ed at the 9:30 o’clock direction, 3 cm away from the 
nipple (Figure 1B). The tumor was isoechogenic, and 
bi-or trilobulated with hypervascularity. The mam-
mography revealed a cluster total number of >20 mi-
crocalcifications at RUOQ. The square area of the le-
sion was 2 cm^2. 
The patient tolerated the treatment well except for 
mild gastrointestinal symptoms, including nausea and 
postprandial abdominal fullness. The nadir of white 
blood cell counts developed after chemotherapy, on 
Day 7 or Day 8: the lowest cell counts dropped to 
1,820/uL (ANC: 500/uL; Band: 0%, Seg: 27.5%), 
which occurred on Day 7 after the second chemother-
apy. Clinically, the patient did not have infection and 
the white cell counts recovered spontaneously two 
weeks later.  
A 
B 
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 She then underwent a modified radical mastecto-
my (MRM) with axillary lymph nodes dissection on 
Sep 11, 2008.  
The surgical pathology showed a breast tissue 
measuring 25 x 20 x 3.0 cm, which was resected. 
There was no visible or palpable tumor in the breast 
tissue. Additionally, there were no viable residual 
cancer cells seen microscopically. The stromal was 
fibrotic and only aggregations of foamy histiocytes 
were observed. No lymphovascular and perineural 
invasion presented. The resection margins were free of 
tumor and the axillary lymph nodes were free of ma-
lignant cells (0/31). The 2002 AJCC stage was 
ypT0N0M0. 
Two more courses of post-operative adjuvant 
chemotherapy were given on Oct 08 and Oct 31, 2008.  
The first adjuvant dose was docetaxel (75 mg/m^2) 
/cisplatin (60 mg/m^2) combined with trastuzumab (4 
mg/kg as the initial loading dose, followed by 2 
mg/m^2 for the maintenance dose). However, grade 
III neutropenia to ANC 439/uL (WBC: 1,520/uL, Seg: 
28.9%) developed on Day 7. Empirical GCSF (100 
mcg) for three days was administered. Thereafter, we 
decreased the dose of docetaxel to 60 mg/m^2 in the 
second course of adjuvant therapy. 
Post-operative local radiotherapy directed to the 
right chest wall, internal mammary chain and right 
supraclavicular fossa was given between November 
2008 and December 2008. The total radiation dose 
applied was 5,000 cGy in 25 fractions, which was 
well-tolerated by the patient except for a mild skin 
reaction. 
After completion of the adjuvant chemotherapy 
and radiotherapy, the patient continued with a 
maintenance level of trastuzumab (6 mg/kg, per three 
week) until June 2009, a total one year treatment 
course. 
We monitored her heart function by echocardio-
gram every three months between June 2008 and April 
2009, and used left ventricular ejection fraction 
(LVEF) as the indicator (with a baseline LVEF of 75% 
in June 2008). During the patient’s trastuzumab 
maintenance treatment, there was no significant dete-
rioration of heart function. The largest drop of ejection 
fraction was 9 percentage points from baseline (66%), 
and it recovered spontaneously. Clinically, the patient 
lacked signs of heart failure, such as dyspnea on exer-
tion, orthopnea, or significant body weight gain.  
Afterwards, she had regular annual follow-up vis-
its, including gynecology exam. Presently, there is no 
evidence of disease recurrence. Additionally, there 
have been no signs of heart failure, electrolyte imbal-
ance or peripheral neuropathy observed. Clinically, the 
patient had good performance with satisfactory re-
sults. 
 
DISCUSSION 
Patients with locally advanced breast cancer have 
poor rates of disease-free survival due to tumor char-
acteristics and nodal status. In previous studies, more 
than 75% of patients with locally advanced breast 
cancer have clinically palpable axillary and/or supra-
clavicular adenopathy. Additionally, more than 65% of 
patients have pathologically confirmed lymph node 
metastasis. Howevere, 25%-30% are diagnosed at an 
inoperable stage [8,9]. Due to the development of 
multimodality therapy, including chemotherapy, radia-
tion therapy and surgery, the overall survival rate for 
the patient population has improved significantly [9]. 
The neoadjuvant treatment approach can provide 
equivalent DFS and OS rates in patients with primary 
operable disease and in those treated with adjuvant 
therapy, but neoadjuvant treatment can provide supe-
rior surgical outcomes [2,3]. 
Pathologic complete response (pCR) is associated 
with long-term survival, and has been adopted as the 
primary endpoint for neoadjuvant trials [10,11]. Cur-
rently, anthracyclin-based and taxane-based therapies 
are most commonly used for patients undergoing ne-
oadjuvant chemotherapy. Multiple studies have 
demonstrated that anthracycline-based regimens in-
corporating a taxane (either concurrently or in se-
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 quence with anthracycline-based regimens) are asso-
ciated with increased response rates in the neoadju-
vant setting [12-14]. A review of the literature [12-14], 
showed that the pCR rates are around 20%~25%. 
The addition of trastuzumab to the treatment of 
HER2 positive cancer in the neoadjuvant setting sig-
nificantly improved the rate of pCR. Trastuzumab, a 
humanized monoclonal antibody directed against the 
external domain of HER-2 protein [15], has been used 
in the neoadjuvant setting for HER2-positive breast 
cancer, and has shown a palpable clinical benefit in 
terms of pathological complete response [5,11,16,17]. 
For instance, the GETN(A)-1 trial, a open-label phase 
II study, disclosed that patients with HER-2-positive, 
stage II/III, noninflammatory, operable breast cancer 
who received trastuzumab plus docetaxel and car-
boplatin achieved promising treatment efficacy, with a 
good pCR rate (39%) and favorable tolerability. Two 
large randomized trials (the TECHNO trial and NOHA 
trial) had reported similar results. The TECHNO trial 
[7] demonstrated a pCR rate of 39%, comparable to 
the findings in other published multicenter studies. In 
the NOHA (Neo Adjuvant Herceptin) trial [18], the 
results demonstrated a doubling of the pCR rate from 
19% to 38% in patients with HER2-overexpressing 
tumors by adding trastuzumab to chemotherapy. 
Moreover, Petrelli F et al. published a meta-analysis to 
evaluate the benefit of adding concomitant trans-
tuzumab to neoadjuvant chemotherapy [19]. This in-
vestigation demonstrated that trastuzumab signifi-
cantly reduces the risk of relapse by 33% and does not 
increase the risk of cardotoxicity in a significant 
manner, despite being associated with anthracyclines. 
Due to concerns about the possibility of cardio-
toxicity, anthracycline and trastuzumab are less fre-
quently used concurrently than in previous clinical 
practice. However, an increasing number of studies [7, 
18-20] have demonstrated that concurrent administra-
tion of anthracycline-based chemotherapy and 
trastuzumab in the neoadjuvant setting is well-    
tolerated. Bayraktar et al. [21] retrospectively evalu-
ated the efficacy of the pCR rates, RFS and OS of pa-
tients receiving neoadjuvant systemic therapy with 
trastuzumab combined with an anthracycline- or 
nonanthracycline-based regimen. They reported that 
although both anthracycline- and nonanthracycline- 
based regimens have shown efficacious results,   
anthracycline-based regimen showed a higher pCR 
rate (60.6% vs. 43.3%, p=0.016) and 3-year RFS ad-
vantage (93% vs. 71%, p<0.01) without any signifi-
cant decline in cardiac ejection fraction. According to 
this retrospective analysis, the safer and more effec-
tive choice may in fact be anthracycline-based chem-
otherapy concomitant with trastuzumab therapy in the 
neoadjuvant setting. But additional data and further 
prospective studies are needed to support these results. 
The benefits of adding trastuzumab to adjuvant 
chemotherapy in patients with HER2-positive tumors 
have been demonstrated in several trials, including 
NCCTG-N9831 [22], NSABP B-31 [22], and BCIRG- 
006 [23]. Based on these trials, 1 year or 52 weeks of 
treatment course was designed. In HERA trial [24], 
which compared adjuvant trastuzumab treatment over 
and 1 and 2 years of adjuvant trastuzumab is not more 
effective than is 1 year of treatment for patients with 
HER2-positive breast cancer. Therefore, one-year or 
52 weeks of adjuvant trastuzumab has remained the 
standard care for HER2-positive breast cancer [25]. 
However, the proper duration of neoadjuvant trastuz-
umab therapy or continuing adjuvant trastuzumab 
therapy is still uncertain. According to the GeparQuat-
tro study [26], the patients with HER2-positive tumors 
received trastuzumab (loading dose 8 mg/kg, mainte-
nance dose 6 mg/kg intravenously every 3 weeks) 
concomitantly to all chemotherapy cycles. A total of 
24 to 36 weeks of pre-operative trastuzumab was used 
and the total pre- and postoperative duration of 
trastuzumab treatment was 1 year. In the NOAH trial, 
33 weeks pre-operative trastuzumab alongside chem-
otherapy were given (loading dose 8 mg/kg, mainte-
nance dose 6 mg/kg intravenously every 3 weeks). 
Additionally, a total 1 year treatment course was also 
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 completed [18]. However, in the TECHNO trial, only 
four 3-week cycles of trastuzumab (loading dose 8 
mg/kg, maintenance dose 6 mg/kg intravenously every 
3 weeks) concomitant with paclitaxel were given be-
fore surgery. Trastuzumab was continued as a single 
agent postoperatively to complete 1 year of treatment 
in this study [7]. The pCR rates in the TECHNO trial 
were as high as those reported in the two trials using a 
longer duration of trastuzumab treatment mentioned 
above (GeparQuattro and NOHA trials) [7]. A pooled 
analysis of the German neoadjuvant trials demon-
strated little evidence to suggest any pCR advantage 
from increasing the number of neoadjuvant 
trastuzumab cycles in HER2-positive disease [25]. To 
date, the most efficacious number of neoadjuvant 
therapy cycles remains uncertain. 
Another anti-HER2 agent, the tyrosine kinase in-
hibitor lapatinib, has been approved for the treatment 
of patients with advanced HER2-positive breast can-
cer [28]. Dual targeting of HER2-positive tumors with 
trastuzumab and lapatinib has been undertaken be-
cause of their partially non-overlapping mechanisms 
of action, and the synergistic antitumor activity in 
HER2 breast cancer models [29]. In the NeoAdjuvant 
Lapatinib and/or Trastuzumab Treatment Optimisation 
(NeoALTTO) study [30], a randomized trial, the in-
vestigators assessed lapatinib, trastuzumab, and in 
combination as neoadjuvant therapy (concomitantly 
used with paclitaxel) for women with HER2-positive 
early breast cancer. The results showed that the pCR 
rate was significantly higher in the combination group 
than in the trastuzumab group and lapatinib group 
(51.3% versus 29.5% and 24.7%, respectively). They 
concluded that dual inhibition of HER2 with lapatinib 
and trastuzumab in combination with paclitaxel is 
better than single-agent HER2 targeting in the neoad-
juvant setting. In another dual HER2 blockade trial, 
NeoSphere neoadjuvant study [31], used a combina-
tion of trastuzumab and pertuzumab. It also showed a 
similar result with a doubling of the pCR rate when 
the two antibodies were given in combination. But the 
disease-free and overall survival endpoints in these 
two trials still necessitate additional follow-up. In ad-
dition, the safety and the tolerability of such dual 
blockade therapy had also been assessed. The TRY-
PHAENA trial [32], was a randomized, multicenter, 
open-label phase II study, which enrolled 225 patients 
with status HER2-positive and operable, locally ad-
vanced, or inflammatory breast cancer. It was de-
signed to evaluate the tolerability and activity associ-
ated with trastuzumab and pertuzumab in combination 
with anthracycline- or carboplatin-based neoadjuvant 
systemic chemotherapy. In this study, the patients 
were randomly allocated into three groups- Arm A: 
5-FU, epirubicin and cyclophosphamide (FEC) fol-
lowed by docetaxel (T), with trastuzumab (H) and 
pertuzumab (P) given concurrently (FEC + H + P x 
3Æ T + H + P × 3); Arm B: FEC followed by T + H+ 
P (FEC x 3→T + H+ P x 3); Arm C: T, carboplatin, H 
with P (TCH + P x 6). The authors reported only two 
patients (2.7%, Arm A) experienced symptomatic left 
ventricular systolic dysfunction and 11 patients (Arm 
A, 4 (5.6%) Arm B, 4 (5.3%) and Arm C, 3 (3.9%)) 
had declines in left ventricular ejection fraction of 
≥10% points from baseline to <50%. The study con-
cluded that the combination of pertuzumab with 
trastuzumab and standard chemotherapy, given con-
currently or sequentially with an anthracycline-based 
chemotherapy regimen, or concurrently with a car-
boplatin-based chemotherapy regimen, resulted in a 
low incidence of left ventricular dysfunction. 
Presently, the intrinsic subtypes of breast cancer 
have been identified based upon variations in gene 
expression. They have distinct behaviors, prognosis 
and responses to therapy. More and more studies have 
shown that pathological complete response rate (pCR) 
predicts recurrence-free survival in different breast 
cancer subtypes [27,33,34]. Aggressive tumor sub-
types (i.e. luminal B/HER2-negative, nonluminal or 
triple negative) are more highly associated with 
event-free survival than smaller, less aggressive tu-
mors (luminal A) [35]. The hazard ratios (HR) for 
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 event-free survival by subtypes, when pCR was 
achieved, were the following: luminal B/HER2(-), 
0.27 (p< .001); nonluminal, 0.39 (p< .001); triple neg-
ative, 0.24 (p< .001) and luminal A, 0.63 (p= .07), 
respectively [35] (Von Minckwitz G et al [33]). 
Demonstrated pCR is a suitable surrogate end point 
for patients with luminal B/HER2-negative (p= .005), 
HER2-positive (nonluminal) (p< .001), and triple- 
negative disease (p< .001) but not for those patients 
with luminal B/HER2-positive (p= .39) or luminal A 
tumors (p= .45). Additionally, pCR in HER2-positive 
(nonluminal) and triple-negative tumors was associ-
ated with excellent prognosis. Because pCR rates of 
neoadjuvant therapies vary in different intrinsic sub-
types of breast cancer, we can effectively tailor the 
treatment according to molecular subtypes after 
well-designed study, hence reducing treatment toxicity 
and avoiding unnecessary costly treatment in the fu-
ture. 
 
CONCLUSIONS 
We reported a case with HER2-positive (nonlu-
minal) locally advanced breast cancer who received 
neoadjuvant chemotherapy containing trastuzumab 
and achieved pathological complete response (pCR), 
followed scheduled surgery and continuing adjuvant 
trastuzumab treatment for a total of one year. Thereaf-
ter, her status has continued disease-free for more than 
3 years. We reviewed the literature about the role of 
trastuzumab/or HER2 blockade in the neoadjuvant 
setting. Most studies showed a clinical benefit in 
terms of pCR. However, the most efficacious duration 
of trastuzumab treatment in the neoadjuvant setting 
remains unclear. Furthermore, use of dual inhibition of 
HER2 (lapatinib or pertuzumab combination with 
trastuzumab) has a higher pCR rate than single agent, 
but we still need additional large randomized trials to 
answer these unresolved-questions. Finally, pCR rates 
of neoadjuvant therapies vary in different intrinsic 
subtypes of breast cancer. However, it may be appro-
priate to tailor patient treatments according to molec-
ular subtypes in a well-designed study, for the purpose 
of reducing treatment toxicity and to avoid unneces-
sary costly treatment in the future. 
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